Research led by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) has shown that therapeutic cloning, also known as somatic-cell nuclear transfer (SCNT), can be used to treat Parkinson’s disease in mice. The study’s results are published in the March 23 online edition of the journal Nature Medicine.
For the first time, researchers showed that therapeutic cloning or SCNT has been successfully used to treat disease in the same subjects from whom the initial cells were derived. While this current work is in animals, it could have future implications as this method may be an effective way to reduce transplant rejection and enhance recovery in other diseases and in other organ systems.
In therapeutic cloning or SCNT, the nucleus of a somatic cell from a donor subject is inserted into an egg from which the nucleus has been removed. This cell then develops into a blastocyst from which embryonic stem cells can be harvested and differentiated for therapeutic purposes. As the genetic information in the resulting stem cells comes from the donor subject, therapeutic cloning or SCNT would yield subject-specific cells that are spared by the immune system after transplantation.
The new study shows that therapeutic cloning can treat Parkinson’s disease in a mouse model. The scientists used skin cells from the tail of the animal to generate customized or autologous dopamine neurons—the missing neurons in Parkinson’s disease. The mice that received neurons derived from individually matched stem cell lines exhibited neurological improvement. But when these neurons were grafted into mice that did not genetically match the transplanted cells, the cells did not survive well and the mice did not recover.
Source: Memorial Sloan-Kettering Cancer Center
Related stories:
Neurons created from skin cells of elderly ALS patients
Less than 27 months after announcing that he had institutional permission to attempt the creation of patient and disease-specific stem cell lines, Harvard Stem Cell Institute (HSCI) Principal Faculty member Kevin Eggan today proclaimed the effort a success - though politically imposed restrictions and scientific advances prompted him to use a different technique than originally planned.
Researchers report the cloning of a key group of human genes, the protein kinases
Although the human genome has been sequenced, research into mechanism of action of genes has been hampered by the fact that most human genes have not been isolated. This is true for even the most common class of cancer-associated genes, the protein kinases, which mediate the majority of signaling events in cells by phosphorylating and modulating the activity of other proteins. It has been estimated by systematic gene sequencing efforts that up to a quarter of kinases may play a role in human cancers.
Ovarian cancer stem cells identified, characterized
Researchers at Yale School of Medicine have identified, characterized and cloned ovarian cancer stem cells and have shown that these stem cells may be the source of ovarian cancer’s recurrence and its resistance to chemotherapy.
A genetic cause for iron deficiency
The discovery of a gene for a rare form of inherited iron deficiency may provide clues to iron deficiency in the general population – particularly iron deficiency that doesn’t respond to iron supplements - and suggests a new treatment approach. The finding was published online by the journal
Nature Genetics on April 13.
Scientists reprogram human skin cells into embryonic stem cells
UCLA stem cell scientists have reprogrammed human skin cells into cells with the same unlimited properties as embryonic stem cells without using embryos or eggs.
Pharmaceutical breakthrough may make a range of drugs cheaper and more available
A new study published in the February 2008 print edition of The FASEB Journal describes a scientific advance that should reduce the cost and increase the availability of a wide range of drugs. In the report, University of Pennsylvania researchers describe how they used gene therapy to reduce the time it takes to breed large animals capable of producing therapeutic proteins in their milk, such as insulin or those that fight cancer. This represents a significant milestone in drug development, as current methods involve cloning, which takes more time and generally costs more.
Scientists find new genetic mutation that halts the development of lupus
The new study was published in the January 18 edition (Volume 28, Issue 1) of the journal
Immunity.
New strategies work to put cancer on the firing line
Dr. Yukai He wants to put cancer in the bull’s eye.“Cancer really comes from us,” the Medical College of Georgia Cancer Center immunologist says of the scary reality that cancer cells are our own cells gone awry. That means our immune system doesn’t always see cancer as a horrific invader.